All posts by PDX Pharmaceuticals
-
PDX Pharma was granted a new EU patent
8/28/2024
PDX Pharma was granted a new EU patent (EP3270932) on August 21, 2024, covering the composition and method of use for our innovative Pdx-NP™ nanoparticle platform. Developed as a polymer-coated mesoporous silica alternative to lipid-based particles, which tend to home to the liver, Pdx-NP™ is the core nanotechnology behind all of PDX Pharmaceuticals’ pipelines. These […]
-
PDX Pharma was granted a new U.S. Patent
8/20/2024
PDX Pharma was granted a new U.S. Patent (US12059500) on August 13, 2024, marking the third U.S. patent for our ARAC™ technology! ARAC™ is based on our innovative Pdx-NP™ nanoparticle platform, which co-delivers antigen release agents and immune checkpoint inhibitors to elicit a potent anti-tumor immune response. The key claims in this patent include PD-L1 […]
-
COO of PDX Pharma has been named on Portland Business Journal’s 40 Under 40 For 2024
7/16/2024
Congratulations to Dr. Worapol (Boom) Ngamcherdtrakul for Being Named a 2024 ’40 Under 40′ Honoree!We are thrilled to announce that our Head of Research & COO, Dr. Worapol Ngamcherdtrakul, has been named one of Portland Business Journal’s prestigious ’40 Under 40′ honorees for 2024! This recognition highlights his exceptional contributions to cancer research and […]
-
Highlights from BIO International 2024
7/2/2024
PDX Pharmaceuticals had a fantastic week at BIO International earlier this month in San Diego! Our Head of Research & COO, Dr. Worapol (Boom) Ngamcherdtrakul, delivered a presentation on our cutting-edge Pdx-NP™ nanoparticle technology, and our lead cancer immunotherapeutic candidate ARAC-02™. The presentation sparked meaningful discussions about how our technology addresses the limitations of […]
-
PDX Pharma has received a Notice of Allowance for the third US patent for ARAC™ technology
6/4/2024
PDX Pharmaceuticals has received a Notice of Allowance for the third US patent for our ARAC™ technology. ARAC™ is based on our nanoparticle platform, Pdx-NP™, co-delivering antigen release agents and immune checkpoint inhibitors to create robust anti-tumor immune response.First in the pipeline is ARAC-02™, which combines a PD-L1 antibody, a PLK1 inhibitor, and an immune-stimulant CpG […]
-
PDX Pharma Received Business Oregon’s SBIR Matching Grant
2/26/2024
PDX Pharmaceuticals has been awarded a Small Business Innovation Research (SBIR) Matching Grant award from Business Oregon. We are proud to be among fourteen companies that won Matching Grants to Support Business Growth and Commercialization. The award will be used for IP protection, marketing, and fundraising activities.
To read more, click here.
-
CEO of PDX Pharma selected as a semi-finalists at the AIM-HI Women’s Venture Competition in Oncology
5/3/2023
Dr. Wassana Yantasee, CEO of PDX Pharmaceuticals, was selected as one of the 6 semi-finalists at the AIM-HI Women’s Venture Competition in Oncology (from among 72 female executives worldwide) by the panel of top cancer experts and VCs based on PDX Pharma’s innovative nano-platform to deliver cancer immunotherapies. The first drug candidate, ARAC-02, targets […]
RECENT PRESENTATIONS ON OUR TECHNOLOGY
Development of antioxidant nanoparticle platform for delivery of siRNA and chemodrugs, Department of Chemistry Seminar Series, Portland State University, May 18th, 2018
Development of a Targeted Therapeutic and Radiation Sensitizer for Lung Cancer, 63rd annual Radiation Research Society (RRS) meeting, Cancun, MX, October 15th, 2017
siRNA-nanoparticles for treating drug-resistant breast cancer, Gordon RNA Technology, Ventura, CA, Feb 1-6. 2015
New methodologies for cancer target identification, personalized medicine in cancer care, and novel therapies based on nanomedicine, BDMS Meeting, Bangkok, Thailand, December 26, 2014 (invited).
OHSU’s effort to understand complex biological systems of cancer leading to targeted therapy with siRNA-nanoparticles, Siriraj School of Medicine, Bangkok, Thailand, December 22, 2014 (invited).
Bioreducible-crosslinked polymer coated mesoporous silica nanoparticles for siRNA targeted delivery to HER2+ breast cancer, 4th International Conference on Nanotek & Expo, San Francisco, CA, December 12, 2014 (invited).
Antibody-conjugated Nanoparticle Platform for Targeted Delivery of SiRNA to HER2+ Breast Cancer, BMES Annual Meeting 2014, San Antonio, TX, October 24, 2014.
SiRNA-mediated Targeting of HER2 as a Viable Approach for Treating Trastuzumab Resistant Breast Cancer, WIN Symposium 2014, Paris, France, June 23, 2014.
Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers, AACR Annual meeting 2014, San Diego, CA, April 9, 2014.
Nanoparticle Platform for siRNA Delivery with ROS Scavenging Properties for Treating Fibrosis, Keystone Symposium, Fibrosis: From Bench to Bedside (C4), Keystone, CO, March 24, 2014.
Development of a Nanoparticle platform for the Targeted Delivery of siRNA to HER2-positive Breast Cancers, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ , March 25, 2014.
Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Mesoporous Silica, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ, March 27, 2014.
Potential Use of Mesoporous Silica Nanoparticle for siRNA Delivery Agent and ROS Scavenger in Fibrotic Diseases, IEEE-Nanomed 2013, Phuket, Thailand, November 11, 2013.
Development of Lanthanide-loaded Mesoporous Silica Nanoparticles for Multi-parametric Single Cell Analysis by Mass Cytometry, IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for targeted delivery of siRNA and chemotherapies, (keynote presentation), IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for therapeutic siRNA delivery to HER2 positive breast cancer, TechConnect World 2012 – Nanotech, Santa Clara, CA, June, 2012.